Peptide News Digest
(Updated )

BPC-157 Pricing: September 2026

BPC-157 runs $39-$55 per research vial, $75-$150 per compounded 5 mg vial, and $199-$350/mo via telehealth. HHS eased enforcement on Oct. 28.

Update (October 29, 2026): HHS will not act against pharmacies that compound BPC-157 under its new policy. On October 28, HHS filed a notice saying it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound BPC-157 or five other peptides, as long as they meet its conditions. The policy does not approve BPC-157 or add it to the 503A bulks list, and HHS can revisit it if safety or quality problems appear. Statements below about the FDA's next steps describe the situation in early September. No pharmacy had posted a price under the new policy by October 29, so the price rows are unchanged. Our explainer on the policy covers the details.

The price picture as of September 2, 2026. BPC-157 (Body Protection Compound-157) is a synthetic peptide copied from a protein in human stomach fluid, and no regulator has approved it for any human use. Prices have barely moved since our April guide. Research vendors sell a 5 mg vial for about $39 and a 10 mg vial for $48 to $55. A compounding pharmacy, which makes the drug to order for one patient's prescription, charges $75 to $150 for a 5 mg vial. Telehealth programs that bundle the visit, the drug, and shipping start near $199 a month and top out around $350. Insurance covers none of it.

What the July vote did and did not do. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend BPC-157 for the Section 503A bulks list. That list names the raw ingredients a licensed pharmacy may use when it compounds a drug for a named patient, while Section 503B covers large outsourcing facilities that make batches without patient-specific prescriptions under a separate list. The vote is advice. The FDA still has to publish a proposed rule, take public comments, and issue a final rule before a pharmacy can legally compound BPC-157. Holland & Knight's August 4 legal note said these peptides "still cannot be lawfully compounded," and no proposed rule had appeared by the end of August. Our piece What the FDA panel's yes vote changed, and what it did not walks through the remaining steps.

Where clinics stand. The pharmacies and telehealth clinics in the tables below sold compounded BPC-157 before the vote and kept selling it afterward at the same prices, though some clinicians want no part of it. On June 25, 2026, UVA Health obesity medicine director Catherine Varney told WSET she will not prescribe BPC-157 or TB-500 because the evidence comes from animal studies. Abroad, Australia's Therapeutic Goods Administration made unapproved peptides a formal compliance priority in June 2026, with BPC-157 heading its list and import seizures and fines among the tools.

What's next. A second PCAC peptide meeting is due before the end of February 2027, covering five other peptides, GHK-Cu among them; BPC-157's vote is already done. For all six recommended peptides in one place, see Post-PCAC 503A peptide pricing 2026, and for the stack with TB-500, see TB-500 pricing. Research-vendor rows below are for market context only, since those products are labeled research use only and are not for human use.

HHS enforcement policy, October 28, 2026

On October 28, 2026, HHS said it will not take enforcement action against 503A pharmacies that compound BPC-157 and five other peptides under set conditions. BPC-157 is still not FDA-approved or on the bulks list, and no pharmacy had posted a price under the policy by October 29.

Channel Price Source
HHS enforcement discretion notice Filed Oct. 28, 2026 Federal Register (public inspection)
What the policy does not do No approval, no list change Federal Register (public inspection)
Conditions for pharmacies Single ingredient, tested source, Rx American Med Spa Association
Multi-peptide blends Outside the stated terms American Med Spa Association
503B outsourcing facilities Not covered NPR via KPBS
Compounded prices under the policy Not yet published NPR via KPBS

After the July 2026 PCAC vote

Status of BPC-157 and the peptides it is usually stacked with, as of September 2, 2026. PCAC is an advisory panel whose votes recommend but do not change the law, so nothing in this table let a pharmacy compound BPC-157. HHS's October 28 policy, in the table above, is a separate step.

Channel Price Source
BPC-157 (PCAC vote, July 23, 2026) Recommended 8-6-1 Medical Daily
TB-500 (PCAC vote, July 23, 2026) Recommended 8-6 Medical Daily
KPV (PCAC vote, July 23, 2026) Recommended 8-6-1 Medical Daily
GHK-Cu Not on the July agenda FDA
Legal effect of the vote Advisory only STAT News
FDA rulemaking status No proposed rule as of August 2026 Holland & Knight
Next PCAC peptide meeting Before end of February 2027 FDA

Telehealth and peptide clinics (prescription plus medication)

Bundled programs that include the consultation, the prescription, the compounded drug, and shipping, which is the most common way patients get BPC-157 with a clinician involved. Prices below match what each page showed on September 2, 2026.

Channel Price Source
Maximus (telehealth) ~$199/mo ClinicLayer
Defy Medical (telehealth) $200–$250/mo ClinicLayer
Med-spa and convenience clinics $150–$350/mo PeakedLabs
Florida Bariatric & Plastic Surgery MD (Palm Beach County) $350/mo Florida Bariatric & Plastic Surgery MD
Specialist peptide clinics $200–$500/mo PeakedLabs
BeyondMD (BPC-157/KPV/TB-500 injectable) From $199/mo BeyondMD

Compounding pharmacies (prescription required)

A 503A pharmacy makes BPC-157 to a prescription for one patient, which is the pathway the PCAC vote addressed. The FDA has not changed the list, but since October 28 HHS says it will not take enforcement action against pharmacies that meet its conditions. These are guide ranges rather than one pharmacy's price list, since pharmacies quote by vial size and concentration.

Channel Price Source
Compounded 5 mg vial $75–$150/vial Pure Peptide Clinic
Compounded 10 mg vial $120–$200/vial Pure Peptide Clinic
Compounded oral capsules (30-day supply) $90–$180 Pure Peptide Clinic
Full program (medication plus monitoring) $200–$600/mo Pure Peptide Clinic
RealPeptides 'compounding pharmacy' tier (5 mg) $90–$140/vial RealPeptides

Oral capsules and sprays

Oral BPC-157 absorbs less than an injection, which is why capsule doses run higher. Two kinds of product appear here: telehealth capsules that need a prescription, and research-labeled capsules sold without one. Integrative Peptides, listed in April, now hides prices behind a professional login, so it is gone from this table.

Channel Price Source
BeyondMD (BPC-157/TB-500 capsules, Rx) From $249/mo BeyondMD
Team Wellcore (BPC-157/TB-500 capsules, Rx) $274/mo Team Wellcore
SwissChems (BPC-157 capsules, research use only) $85.95/60 capsules SwissChems

Research peptide vendors (research use only)

Sold for laboratory research, not for human use, and included for market context only; prices are per vial of freeze-dried powder that must be mixed with bacteriostatic water. Limitless Life Nootropics, listed in April, now shows prices only to logged-in professional accounts, so it was dropped.

Channel Price Source
Bluum Peptides (5 mg) $39/vial Bluum Peptides
Ion Peptides (10 mg) $48/vial Peptide Grades
Verified Peptides (10 mg) $53/vial Peptide Grades
Alpha Omega Peptide (10 mg) $55/vial Alpha Omega Peptide
SwissChems (BPC-157 + TB-500 blend) $119.95/vial SwissChems
Market range (5 mg research vial) $38–$95/vial RealPeptides